Pharmacogenomics Challenges and Opportunities in Therapeutic Implementation

The book chapters are organized into several major sections. Section 1 (chapters 1 to 3) provides an introductory chapter on pharmacogenomics, an overview chapter on the challenges of moving the discipline into real-world settings over the last decade, and a chapter on global academic and governmental efforts to advance and apply the relevant genomic knowledge. Section 2 (chapters 4 to 7) primarily focuses on clinical areas where the evidence strongly supports direct pharmacogenetic applications to patient care. Where appropriate, unsuccessful applications are used to illustrate the challenges for the discipline. In addition, this section also contains three Looking to the Future subchapters that describe the concepts and challenges of integrating epigenetics into pharmacogenomics studies for the cardiology, oncology, and psychiatry disciplines. Section 3 (chapters 8 and 9) provides perspective and insights on study design,statistical models, as well as molecular approaches and techniques in pharmacogenomics research and drug development. Section 4 (chapters 10 to 12) is a unique section that covers the diverse topics of ethnobridging, health technology assessment, and governance of personalized medicine. Last but not least, the final section (chapter 13) discusses an example of how genomic education has been integrated into a pharmacy curriculum and provides a framework of how this textbook can be useful for teaching pharmacogenomics to students in various health care disciplines and graduate-level students in health and pharmaceutical sciences. To facilitate learning, each chapter also contains objectives and discussion points. Additional material, including elaboration on discussion points, and patient case scenarios illustrating how pharmacogenetics may be clinically applied, are available on the website (

Type Book
CME Available No
Cost $94.93 - Hardcover

Date of Resource 2013

Genomic Competencies

Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.


  • Basic Genetic Concepts
    • B2:   To recognize and appreciate the role of behavioral, social, and environmental factors (lifestyle, socioeconomic factors, pollutants, etc.) to modify or influence genetics in the manifestation of disease
    • B3:   To identify drug and disease associated genetic variations that facilitate development of prevention, diagnostic and treatment strategies and appreciate there are differences in testing methodologies and are aware of the need to explore these differences in drug literature evaluation
  • Ethical, Legal and Social Implications (ELSI)
    • E1:   To understand the potential physical and/or psychosocial benefits, limitations and risk of genomic/pharmacogenomic information for individuals, family members and communities, especially with genomic/pharmacogenomic tests that may relate to predisposition to disease
    • E4:   To appreciate the cost, cost-effectiveness, and reimbursement by insurers relevant to genomic or pharmacogenomic tests and test interpretation, for patients and populations
  • Genetics and Disease
    • G1:   To understand the role of genetic factors in maintaining health and preventing disease
    • G2:   To assess the difference between clinical diagnosis of disease and identification of genetic predisposition to disease (genetic variation is not strictly correlated with disease manifestation)
    • G3:   To appreciate that pharmacogenomic testing may also reveal certain genetic disease predispositions (e.g. the Apo E4 polymorphism)